2. Academic Validation
  3. Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia

Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia

  • Bioorg Chem. 2026 Jun 5:173:109588. doi: 10.1016/j.bioorg.2026.109588.
Ming-Jie Huang 1,  Jian Song 2,  Meiqi Jia 2,  Sai-Yang Zhang 3,  Lihua Huang 4
Affiliations

Affiliations

  • 1 Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou 450046, China; Henan Key Laboratory of Individualized Drug Therapy for Cardiovascular Diseases, Zhengzhou 450046, China. Electronic address: mjhuang2025@163.com.
  • 2 School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, PR China.
  • 3 School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, PR China. Electronic address: saiyangz@zzu.edu.cn.
  • 4 Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China; Henan International Joint Laboratory of Tumor Theranostical Cluster Materials; College of Chemistry, Zhengzhou University, Zhengzhou, Henan 450001, PR China.. Electronic address: hlh606@zzu.edu.cn.
PMID: 41671737 DOI: 10.1016/j.bioorg.2026.109588
Abstract

Lysine-specific demethylase 1 (LSD1), a key epigenetic regulator mediating histone modification, has been a potential therapeutic target for acute myeloid leukemia (AML) due to its critical role in disease pathogenesis. In this work, we designed and synthesized novel LSD1 inhibitors with the scaffold of tranylcypromine-pyrimidine. The representative compound 7a was a highly effective LSD1 inhibitor (IC50 = 7.87 nM) with excellent selectivity over MAO-A and MAO-B (>127-fold over MAO-A and > 1270-fold over MAO-B). Meanwhile, compound 7a also showed effective inhibitory activity against MV-4-11 with IC50 values of 0.36 μM. Mechanistic studies demonstrated that 7a could directly targeted LSD1, thereby promoting a significant increase of H3K4me1/2 histone methylation levels in MV-4-11 cells. 7a induced Apoptosis while upregulating the differentiation marker CD86 and downregulating the stem cell-associated proteins SOX2 and CD44. Collectively, these findings establish compound 7a, a tranylcypromine-pyrimidine derivative, provides the structural foundation for the development of LSD1 inhibitors for the treatment of AML.

Keywords

Activities; Acute myeloid leukemia; LSD1; Pyrimidine; Tranylcypromine.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z